NCT05703282View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of AD-104-A

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions

Hyperlipidemias

Interventions

DRUG

AD-104-A

PO, Single-Dose, AD-104-A

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY